CD8
CD226 antigen
Colorectal Neoplasms
Liver metastasis
Lymphocytes
Tumor-Infiltrating
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
04
07
2022
accepted:
03
01
2023
medline:
4
4
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
CD226 has been reported to participate in the rescue of CD8
Identifiants
pubmed: 36717657
doi: 10.1038/s41423-023-00978-2
pii: 10.1038/s41423-023-00978-2
pmc: PMC10066387
doi:
Substances chimiques
Receptors, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-378Informations de copyright
© 2023. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.
pubmed: 35020204
doi: 10.3322/caac.21708
Chakedis J, Schmidt CR. Surgical treatment of metastatic colorectal cancer. Surgical Oncol Clin North Am. 2018;27:377–99.
doi: 10.1016/j.soc.2017.11.010
Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:2524–30.
pubmed: 19568816
doi: 10.1245/s10434-009-0585-3
Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670–7.
pubmed: 21846824
doi: 10.1158/0008-5472.CAN-11-0268
Galon J. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–4.
pubmed: 17008531
doi: 10.1126/science.1129139
Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol. 2018;36:247–77.
pubmed: 29328785
doi: 10.1146/annurev-immunol-051116-052415
Simpson JAD, Al-Attar A, Watson NFS, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 2010;59:926–33.
pubmed: 20581241
doi: 10.1136/gut.2009.194472
Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017;8:15107. 31
pubmed: 28561063
pmcid: 5499209
doi: 10.1038/ncomms15107
Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, et al. Evolution of metastases in space and time under immune selection. Cell 2018;175:751–765.e16.
pubmed: 30318143
doi: 10.1016/j.cell.2018.09.018
Chiang EY, Mellman I. TIGIT-CD226-PVR axis: Advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10:e004711.
pubmed: 35379739
pmcid: 8981293
doi: 10.1136/jitc-2022-004711
Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, et al. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers (Basel). 2019;11:877.
pubmed: 31234588
doi: 10.3390/cancers11060877
Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16:40–52.
pubmed: 30275538
doi: 10.1038/s41423-018-0168-y
Guillamón CF, Martínez-Sánchez MV, Gimeno L, Mrowiec A, Martínez-García J, Server-Pastor G, et al. NK cell education in tumor immune surveillance: DNAM-1/KIR Receptor ratios as predictive biomarkers for solid tumor outcome. Cancer Immunol Res. 2018;6:1537–47.
pubmed: 30242020
doi: 10.1158/2326-6066.CIR-18-0022
Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8
pubmed: 25866972
pmcid: 4463210
doi: 10.1172/JCI80445
Jin HS, Ko M, Choi DS, Kim JH, Lee DH, Kang SH, et al. CD226hiCD8+ T cells are a prerequisite for anti-TIGIT immunotherapy. Cancer Immunol Res. 2020;8:912–25.
Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008;205:2965–73.
pubmed: 19029380
pmcid: 2605240
doi: 10.1084/jem.20081752
Wang B, Zhang W, Jankovic V, Golubov J, Poon P, Oswald EM, et al. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype. Sci Immunol. 2018;3:eaat7061.
pubmed: 30389797
doi: 10.1126/sciimmunol.aat7061
Weulersse M, Asrir A, Pichler AC, Lemaitre L, Braun M, Carrié N, et al. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity 2020;53:824–39.
pubmed: 33053331
doi: 10.1016/j.immuni.2020.09.006
Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O’Gorman WE, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity 2022;55:512–26.
pubmed: 35263569
pmcid: 9287124
doi: 10.1016/j.immuni.2022.02.005
Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, et al. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. Immunity 2020;53:805–23.
pubmed: 33053330
doi: 10.1016/j.immuni.2020.09.010
Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, et al. CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol. 2018;190:64–73.
pubmed: 28893624
doi: 10.1016/j.clim.2017.08.021
Ayano M, Tsukamoto H, Kohno K, Ueda N, Tanaka A, Mitoma H, et al. Increased CD226 Expression on CD8+ T Cells Is Associated with Upregulated Cytokine Production and Endothelial Cell Injury in Patients with Systemic Sclerosis. J Immunol. 2015;195:892–900.
pubmed: 26109642
doi: 10.4049/jimmunol.1403046
Bi J. CD226: a potent driver of antitumor immunity that needs to be maintained. Cell Mol Immunol. 2022;19:969–70.
Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332–42.
pubmed: 12843795
pmcid: 2305721
doi: 10.1097/00002371-200307000-00005
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: An R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71–e71.
pubmed: 26704973
doi: 10.1093/nar/gkv1507
Valpione S, Mundra PA, Galvani E, Campana LG, Lorigan P, De Rosa F, et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun. 2021;12:4098.
pubmed: 34215730
pmcid: 8253860
doi: 10.1038/s41467-021-24343-x
Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics 2019;35:i436–45.
pubmed: 31510660
pmcid: 6612828
doi: 10.1093/bioinformatics/btz363
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.
pubmed: 27765066
pmcid: 5073889
doi: 10.1186/s13059-016-1070-5
Che LH, Liu JW, Huo JP, Luo R, Xu RM, He C, et al. A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy. Cell Disco. 2021;7:80.
doi: 10.1038/s41421-021-00312-y
Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell 2021;184:3573–87.
pubmed: 34062119
pmcid: 8238499
doi: 10.1016/j.cell.2021.04.048
Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289–96.
pubmed: 31740819
pmcid: 6884693
doi: 10.1038/s41592-019-0619-0
Hudson WH, Gensheimer J, Hashimoto M, Wieland A, Valanparambil RM, Li P, et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ Stem-like CD8+ T cells during chronic infection. Immunity 2019;51:1043–58.
pubmed: 31810882
pmcid: 6920571
doi: 10.1016/j.immuni.2019.11.002
Triki H, Charfi S, Bouzidi L, Ben Kridis W, Daoud J, Chaabane K, et al. CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. Life Sci. 2019;231:116543.
pubmed: 31176775
doi: 10.1016/j.lfs.2019.116543
Bindea G, Mlecnik B, Galon J. Expand to shield: IL-15 and in situ lymphocytic proliferation. OncoImmunology 2021;10:1886726.
pubmed: 33628626
pmcid: 7889171
doi: 10.1080/2162402X.2021.1886726
Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, et al. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open. 2021;6:100156.
pubmed: 34044286
pmcid: 8167159
doi: 10.1016/j.esmoop.2021.100156
El-Jawhari JJ, El-Sherbiny YM, Scott GB, Morgan RSM, Prestwich R, Bowles PA, et al. Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Mol Immunol. 2014;58:160–8.
pubmed: 24365750
doi: 10.1016/j.molimm.2013.11.020
Nomoto D, Baba Y, Okadome K, Yagi T, Kalikawe R, Kiyozumi Y, et al. Prognostic Impact of PD-1 on tumor-infiltrating lymphocytes in 433 resected esophageal cancers. Ann Thorac Surg. 2022;113:286–94.
pubmed: 33482156
doi: 10.1016/j.athoracsur.2021.01.013
Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang YT, Lewik G, et al. PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. Oncoimmunology 2017;6:e1331194.
pubmed: 28932634
pmcid: 5599080
doi: 10.1080/2162402X.2017.1331194
Laumont CM, Wouters MCA, Smazynski J, Gierc NS, Chavez EA, Chong LC, et al. Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. Clin Cancer Res. 2021;27:4089–100.
pubmed: 33963000
doi: 10.1158/1078-0432.CCR-20-4394
Martin de la Fuente L, Westbom-Fremer S, Arildsen NS, Hartman L, Malander S, Kannisto P, et al. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Virchows Arch. 2020;477:83–91.
pubmed: 31980961
pmcid: 7320055
doi: 10.1007/s00428-020-02751-6
Brockhoff G, Seitz S, Weber F, Zeman F, Klinkhammer-Schalke M, Ortmann O, et al. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotarget 2018;9:6201–12.
pubmed: 29464065
doi: 10.18632/oncotarget.23717
Zander R, Khatun A, Kasmani MY, Chen Y, Cui W. Delineating the transcriptional landscape and clonal diversity of virus-specific CD4+ T cells during chronic viral infection. eLife 2022;11:e80079.
pubmed: 36255051
pmcid: 9629829
doi: 10.7554/eLife.80079
Zhang Z, Chen L, Chen H, Zhao J, Li K, Sun J, et al. Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. eBioMedicine 2022;83:104207.
pubmed: 35961204
pmcid: 9382263
doi: 10.1016/j.ebiom.2022.104207
Feng M, Wu Z, Zhou Y, Wei Z, Tian E, Mei S, et al. BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. Sig Transduct Target Ther 2021;6:313.
doi: 10.1038/s41392-021-00730-0